Landmark analyses of PFS with ixazomib vs placebo. Landmark analysis based on MRD status at (A) 14 months and (B) 28 months in patients who received ixazomib vs placebo in the TOURMALINE-MM3 and -MM4 trials. inf, infinity; NR, not reached. ∗HR, of MRD⁻ with ixazomib vs placebo unstable due to small event numbers.